Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2021 Filed Apr 26, 2021 20:03 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionCommon stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC |
Chu Yu-WayeSenior VP Clinical Development
|
SaleCommon stock | 1,500 | $84.41 | $126,615.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 3 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.635 to $84.61 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC |
Chu Yu-WayeSenior VP Clinical Development
|
SaleCommon stock | 900 | $82.91 | $74,619.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,300 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.6175 to $83.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC |
Chu Yu-WayeSenior VP Clinical Development
|
SaleCommon stock | 875 | $81.80 | $71,575.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,200 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.395 to $82.205 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
Exercise / conversionStock Option Right to Buy · Derivative | 1,851 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 12 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,458 Underlying: Common Stock · 1,851 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F11 · derivative.exercise_date: 1/2 of the shares subject to this option vested in 48 equal monthly installments beginning on November 4, 2013. The remaining 1/2 of the shares are divided into five equal parts, and 1/5 of such remaining shares vested in 24 equal monthly installments following the Issuer's achievement of one of the five specified performance based milestones. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 28,149 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 11 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,149 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F10 · derivative.exercise_date: The shares subject to this option vested in 48 equal monthly installments beginning on February 8, 2016. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 400 | $87.45 | $34,979.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 10 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F9 · price: Represents the weighted average sale price of the shares sold ranging from $87.36 to $87.53 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 5,299 | $86.76 | $459,732.76 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 9 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,448 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $86.34 to $87.32 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 4,835 | $85.98 | $415,732.64 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 8 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,747 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $85.34 to $86.33 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 2,200 | $84.48 | $185,865.02 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 7 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,582 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $84.08 to $84.97 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 3,490 | $83.40 | $291,080.31 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,782 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $83.08 to $84.06 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 4,556 | $82.69 | $376,714.23 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,272 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $82.08 to $83.07 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 8,220 | $81.48 | $669,731.08 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,828 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $81.02 to $81.85 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
SaleCommon Stock | 1,000 | $80.49 | $80,494.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $80.02 to $81.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 9. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
Exercise / conversionCommon Stock | 1,851 | $7.87 | $14,567.37 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC |
TAHL CINDYSee Remarks
|
Exercise / conversionCommon Stock | 28,149 | $2.90 | $81,632.10 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · derivative · entry 7 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,156 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
SaleCommon Stock | 1,018 | $94.59 | $96,297.10 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,740 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F6 · price: Represents the weighted average sale price of the shares sold from $94.40 to $94.90 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
SaleCommon Stock | 3,205 | $93.75 | $300,460.74 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F5 · price: Represents the weighted average sale price of the shares sold from $93.31 to $94.29 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
SaleCommon Stock | 8,404 | $92.64 | $778,577.65 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,963 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $92.31 to $93.27 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
SaleCommon Stock | 8,416 | $91.94 | $773,782.19 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,367 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $91.30 to $92.29 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
SaleCommon Stock | 3,957 | $90.89 | $359,654.50 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $90.30 to $91.29 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC |
Valamehr BahramChief Development Officer
|
Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 800 | $86.70 | $69,360.00 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 8 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,020 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 2,900 | $85.50 | $247,956.09 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 7 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,820 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 2,728 | $84.20 | $229,704.69 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 6 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,720 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 2,480 | $83.46 | $206,989.48 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 5 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,448 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 2,993 | $81.60 | $244,224.31 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 4 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,928 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 5,174 | $80.73 | $417,722.37 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,921 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 4,627 | $79.58 | $368,235.63 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,095 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC |
Shoemaker Daniel DChief Scientific Officer
|
SaleCommon stock | 3,298 | $78.60 | $259,235.66 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,722 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · derivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 20,000 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Not applicable. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 5,547 | $103.16 | $572,205.78 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $102.86 to $103.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 8,602 | $102.26 | $879,661.16 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,340 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $101.85 to $102.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 2,602 | $101.42 | $263,883.39 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,942 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $100.83 to $101.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 1,848 | $100.48 | $185,690.92 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,544 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $99.825 to $100.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 1,401 | $99.08 | $138,816.96 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,392 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $98.65 to $99.645 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionCommon stock | 20,000 | $6.62 | $132,400.00 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 20 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,846 Underlying: Common Stock · 20,000 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 19 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 3,075 | $100.01 | $307,544.90 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 16 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F14 · price: Represents the weighted average sale price of the shares sold ranging from $99.81 to $100.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 6,520 | $99.35 | $647,732.01 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 15 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,868 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F13 · price: Represents the weighted average sale price of the shares sold ranging from $98.80 to $99.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 7,638 | $98.45 | $751,951.93 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 14 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,388 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F12 · price: Represents the weighted average sale price of the shares sold ranging from $97.80 to $98.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 12,767 | $97.23 | $1,241,382.65 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 13 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,026 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F11 · price: Represents the weighted average sale price of the shares sold ranging from $96.77 to $97.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionCommon stock | 20,000 | $6.62 | $132,400.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 12 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionCommon stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 11 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 18 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 200 | $106.96 | $21,391.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F10 · price: Represents the weighted average sale price of the shares sold ranging from $106.84 to $107.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 645 | $106.03 | $68,391.80 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,993 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F9 · price: Represents the weighted average sale price of the shares sold ranging from $105.75 to $106.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC |
Wolchko J ScottDirector · President and CEO
|
SaleCommon stock | 4,271 | $105.25 | $449,516.77 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,638 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $104.75 to $105.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.